Aviral Singh

¹⁷⁷Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt et al. · Journal of Nuclear Medicine · 2016 · 526 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results

Richard P. Baum, Christiane Schuchardt, Aviral Singh et al. · Journal of Nuclear Medicine · 2021 · 327 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

Mike Sathekge, Ismaheel O. Lawal, Chandrasekhar Bal et al. · The Lancet Oncology · 2024 · 178 citations

Medicine, Oncology, Urology +17

Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results

Berthold A. Nock, Aikaterini Kaloudi, Emmanouil Lymperis et al. · Journal of Nuclear Medicine · 2016 · 167 citations · Full text

Medicine, Oncology, Pharmacology +17

Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms

Richard P. Baum, Harshad Kulkarni, Aviral Singh et al. · Oncotarget · 2018 · 139 citations · Full text

Medicine, Nuclear Medicine, Oncology +17